1. Name and Address of Reporting Person

Kamal Mostafa

4801 EAST WASHINGTON STREET

PHOENIX AZ 85034

2. Issuer Name and Ticker or Trading Symbol

MAGELLAN HEALTH INC [ MGLN ]

5. Relationship of Reporting Person(s) to Issuer

Director

Officer (give title below)

Other (specify below)

CEO, Magellan Rx Management

3. Date of Earliest Transaction (Month/Day/Year)

11/10/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 4)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Common Stock, $0.01 par value</td>
<td>11/10/2020</td>
<td>x(1)</td>
<td>A</td>
<td>$66.57</td>
<td>11,617</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Ordinary Common Stock, $0.01 par value</td>
<td>11/10/2020</td>
<td>g(1)</td>
<td>D</td>
<td>$81.57</td>
<td>5,617</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>$66.57</td>
<td>11/10/2020</td>
<td>x(1)</td>
<td>6,000</td>
<td>(2)</td>
<td>03/05/2029</td>
<td>Common Stock</td>
<td>6,000</td>
<td>$0.00(1)</td>
<td>34,808</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
2. Of the 13,603 stock options that vested on March 5, 2020, 7,603 remain available to exercise after the reported transaction. The remainder of 27,205 options shall vest in equal increments on March 3, 2021 and 2022.
3. Not applicable.

Remarks:

/s/ Mostafa Kamal

11/12/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.